Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Lakewood-Amedex Biotherapeutics Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Lakewood-Amedex Biotherapeutics announced the launch of Nu-3, a topically delivered antimicrobial gel for treating infected diabetic foot ulcers, supported by preclinical and clinical data and backed by the company's intellectual property portfolio in drug-resistant infection treatment.
Key Takeaways
Nu-3 is the company's lead program targeting infected diabetic foot ulcers, a significant unmet medical need with serious patient risks
The product launch is supported by extensive preclinical and clinical data demonstrating efficacy
2 more takeaways